MicroRNA for Prediction of Teratoma and Viable Germ Cell Tumor after Chemotherapy

Urol Clin North Am. 2024 Aug;51(3):387-394. doi: 10.1016/j.ucl.2024.03.007. Epub 2024 Apr 16.

Abstract

MicroRNAs (miRNAs) are emerging as highly sensitive and specific markers for testicular germ cell tumors (GCTs) across the spectrum of disease. However, their utility in specific clinical scenarios requires further study. Here, we review the current evidence for miRNAs as tumor markers for the evaluation of treatment response in patients undergoing chemotherapy for the treatment of advanced testicular GCT.

Keywords: Cisplatin-resistance; Germ cell tumors; Retroperitoneal lymph node dissection (RPLND); Testicular cancer; Tumor markers; miRNA.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor* / analysis
  • Biomarkers, Tumor* / genetics
  • Humans
  • Male
  • MicroRNAs* / genetics
  • Neoplasms, Germ Cell and Embryonal* / drug therapy
  • Neoplasms, Germ Cell and Embryonal* / genetics
  • Neoplasms, Germ Cell and Embryonal* / pathology
  • Teratoma* / drug therapy
  • Teratoma* / genetics
  • Teratoma* / pathology
  • Testicular Neoplasms* / drug therapy
  • Testicular Neoplasms* / genetics
  • Testicular Neoplasms* / pathology

Substances

  • MicroRNAs
  • Biomarkers, Tumor

Supplementary concepts

  • Testicular Germ Cell Tumor